Q-Sera has the support of leading Australian Investors, Uniseed and Brandon BioCatalyst (formerly known as the Medical Research Commercialization Fund (MRCF)).
UniQuest is the commercialisation company of The University of Queensland (UQ). In partnership with UQ researchers, we create impact through the commercialisation of UQ intellectual property (IP). Established in 1984, UniQuest’s commercialisation track record positions UQ as the leader of research commercialisation in Australasia. UniQuest has formed more than 125 start-up companies built on UQ IP. These companies have raised more than A$965 million to advance UQ technologies towards the market and have directly created more than 450 new jobs. UniQuest’s track record and notable successes include the blockbuster cervical cancer vaccine GARDASIL® and start-up companies Spinifex Pharmaceuticals Inc and Inflazome Ltd, which were acquired in two of the largest university start-up exits in Australian history.
Marketed products containing UQ IP licensed by UniQuest have generated gross sales of more than A$57 billion, significantly contributing to societal and economic impact. UniQuest has also established the Queensland Emory Drug Discovery Initiative (QEDDI), a world-class small molecule drug discovery and development group, dedicated to translating academic biomedical research into drug candidates for partnering.